Ladenburg - Heidelberg Pharma AG (FWB: HPHA) announced today announced that she was supported by her partner Magenta Therapeutics, Cambridge, MA, USA, (Magenta) (NASDAQ: MGTA) with the start of the GLP toxicology study with the Development candidate MGTA-117 has received a milestone payment.

Prof. Andreas Pahl, Head of Research & Development at Heidelberg Pharma, commented, 'We are pleased that Magenta is advancing MGTA-117 towards of clinical trials. The antibody based on our ATAC technology Amanitin Conjugate MGTA-117 is intended for targeted conditioning of patients who have a Stem cell transplant for blood cancer or genetic diseases need to be developed.

About Magenta Therapeutics

Magenta Therapeutics, headquartered in Cambridge, MA, USA, is a Clinical stage biotechnology company developing novel drugs for Patients with autoimmune diseases, blood cancer and genetic diseases developed.

By building a platform that will target critical areas of uncovered medical Magenta Therapeutics is pioneering an integrated approach that to enable more patients to receive a one-time, curative immune reset.

About Heidelberg Pharma's proprietary ATAC technology

Antibody-drug conjugates (Antibody Drug Conjugates - ADCs) combine the high Affinity and specificity of antibodies with the effectiveness of small toxic molecules, to fight cancer. ATACs (Antibody Targeted Amanitin Conjugates) are ADCs whose Active ingredient consists of amatoxin molecules. Amatoxins are bicyclic peptides found in the Naturally occurring in the green leaf agaric. By binding to the RNA polymerase II

They inhibit the transcription of the mRNA, a mechanism that is crucial for the Survival of eukaryotic cells is. In preclinical studies, ATACs have a very shown to be highly effective; they overcame common mechanisms of resistance and can also fight dormant tumor cells.

About Heidelberg Pharma

Heidelberg Pharma AG is a biopharmaceutical company based in Ladenburg.

Heidelberg Pharma specializes in oncology and is the first company to offer the Active ingredient Amanitin is used and developed for use in cancer therapies. Therefore the company uses its innovative ATAC technology (Antibody Targeted Amanitin Conjugates) and uses the toxin's biological mechanism of action as a new one therapeutic principle. This proprietary technology platform is used for development own therapeutic antibody-drug conjugates as well as in the context of Collaborations with external partners used to attract a wide variety of ATAC candidates produce. The most advanced proprietary product candidate, HDP-101, is a BCMA ATAC for the multiple myeloma indication. Heidelberg Pharma AG is based on the Frankfurt Stock exchange listed: ISIN DE000A11QVV0 / WKN A11QVV / symbol WL6.

Contact:

Sylvia Wimmer

Tel: +49 89 41 31 38-29

Email: investors [at] hdpharma.com

This text contains certain forward-looking statements that relate to the business of the company and which, through the use of forward-looking terminology such as 'estimates', 'believes', 'Expected', 'could', 'will', 'should', 'future', 'possible' or similar expressions or by some general Award presentation of the company's strategy, plans, and intentions. Such forward-looking Statements include known and unknown risks, uncertainties, and other factors that may result could that the actual results of business operations, the financial position, the earnings position, the Achievements or even the results of the sector differ significantly from any future results, Income or accomplishments that are expressed or expressed in such forward-looking statements are assumed. Given these imponderables, potential investors and partners are in front of it cautioned against placing undue reliance on such forward-looking statements. We don't take on any Obligation to update such forward-looking statements to reflect future events or To reflect developments.

(C) 2020 Electronic News Publishing, source ENP Newswire